NCT02627872Active, not recruiting
Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 28 Mar 2025
Brief summary (registry, in English)
Chronic Obstructive Pulmonary Disease (COPD) is an increasing global health problem, which primarily increases among the female population. The purpose of this study is to perform in-depth clinical and molecular characterizations of early stage COPD patients, as well as healthy never-smoker and at-risk smoking control populations to identify molecularly related subgroups patients, including gender-related sub-phenotypes of COPD.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 120 (actual)
- First submitted
- 9 Dec 2015
- Start date
- 1 Mar 2007
- Primary completion date
- 31 Dec 2021
- Lead sponsor
- Karolinska Institutet
- Diseases
- COPD
- NCT number
- NCT02627872
What you commit to
- Study type: Observational
- Participants enrolled: 120
- From 1 Mar 2007 to the primary completion date, 31 Dec 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received antibiotics for a COPD exacerbation in the 3 months prior to study entry
- Treatment with oral or inhaled glucocorticoids within past 3 months prior to study entry
Other illness
- Other lung diseases
- Significant ischaemic heart disease or arrhythmia
Other
- Atopy (defined as positive specific IgE test)
- Asthma
Who the study is looking for
- For smokers, at least 10 pack-years of cigarette smoking
- For smokers, at least 10 cigarettes/day the past 6 months before study entry Spirometry that meets stage I-II of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (postbronchodilator forced expiratory volume in 1 second (FEV1) of 50%-100% of predicted level and FEV1/forced vital capacity \[FEV1/FVC\] less than 0.7) or normal (postbronchodilator FEV1 greater than 80% of predicted level and forced expiratory volume in 1 second/forced vital capacity \[FEV1/FVC\] greater than 0.7)
Age in the registry: 45 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet/Karolinska University Hospital Solna Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.